Metamizol Kalceks (Metamizole Sodium Monohydrate)

Metamizole sodium works primarily by inhibiting cyclooxygenase enzymes, which reduces prostaglandin production. This decrease in prostaglandins lessens pain signaling and lowers the hypothalamic set‑point for temperature, providing analgesic and antipyretic effects.

The dosage of Metamizol Kalceks is determined by the prescribing clinician based on the patient’s condition, age, weight, and response. Healthcare professionals adjust the amount and frequency to achieve effective pain relief or fever control.

Safety data for metamizole sodium during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and under medical supervision.

To order Metamizol Kalceks, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metamizole belongs to the pyrazolone class and offers strong analgesic and antipyretic effects without engaging opioid receptors. Compared with NSAIDs, it may have a lower risk of gastrointestinal irritation but carries a unique risk of blood dyscrasias such as agranulocytosis, which is not typical for many other non‑opioid analgesics.

Metamizol Kalceks should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and physical damage. Follow standard aseptic techniques when preparing for intramuscular or intravenous administration.

Metamizol Kalceks is supplied as an injectable solution for intramuscular or intravenous injection. The route, volume, and rate of administration are determined by the prescriber, who may choose a single dose or repeated dosing based on the clinical situation.

The most serious adverse reactions include agranulocytosis, severe skin disorders such as Stevens‑Johnson syndrome, and anaphylactic shock. These events are rare but can be life‑threatening, requiring immediate medical attention and discontinuation of the drug.

Patients with a known hypersensitivity to metamizole or other pyrazolones, those with a history of severe blood disorders, and individuals currently receiving other myelosuppressive agents should avoid Metamizol Kalceks. Caution is also advised for patients with significant renal or hepatic impairment.